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Current classes of chemotherapeutic agents offer limited thera-
peutic benefit for many human malignancies. New classes of
agents with diverse structures and molecular targets are, therefore,
of interest in the pursuit of improved anticancer agents. While
empirical evaluation of the clinical efficacy of such new
compounds still forms the cornerstone of their development as
therapeutic agents, an understanding of their molecular mecha-
nism of action is important to developing rational strategies for
clinical evaluation.
FR901228 (NSC 630176), is a cytotoxic depsipeptide isolated by
the Fujisawa Pharmaceutical Company from the fermentation broth
of Chromobacterium violaceum (Ueda et al, 1994b). Initial charac-
terization of the compound showed it to be cytotoxic at nanomolar
concentrations in several in vitro and in vivo models (Ueda et al,
1994a,b). FR901228 was found to downregulate c-myc mRNA and
to cause a G1 cell cycle arrest in H-ras transformed NIH 3T3 cells
(Ueda et al, 1994c) and also to downregulate c-myc in activated T
lymphocytes (Wang et al, 1998). The products of several onco-
genes have been identified as components of signal transduction
pathways, or of autocrine loops involving signal transduction path-
ways (Hunter, 1997). For example, the oncogenes ErbB2, Ras and
Raf are components of the mitogen activated protein kinase (MAP
kinase) pathway that have been subverted by mutation or over-
expression, provoking uncontrolled signalling. Activation of the
MAPK pathway induces cyclin D1 (Aktas et al, 1997; Zou et al,
1997) which in turn activates CDK causing Rb phosphorylation,
determining the restriction point in moving from G1 into S phase
(Weinberg, 1995). Phosphorylation of Rb causes release of the E2F
transcription factor (Nevins, 1998). This transcriptionally induces
c-myc and other genes that are required for initiation of DNA
synthesis (Johnson et al, 1993; Oswald et al, 1994; Weinberg,
1995). In contrast, downregulation of cyclin D1 or upregulation of
CDK inhibitors such as p21 causes Rb dephosphorylation and
growth arrest (Sherr, 1999).
Histone acetylation, originally discovered in 1964, provides an
enzymatic mechanism to regulate transcription by affecting the
interaction between DNA and histones. Recently, it has been deter-
mined that dephosphorylated Rb bound to E2F associates with a
histone deacetylase to effect transcriptional repression (Brehm et
al, 1998; Luo et al, 1998; Magnaghi-Jaulin et al, 1998). Inhibitors
of histone deacetylase, although counterintuitive, have the capacity
to inhibit cell growth while increasing gene expression. Several
histone deacetylase (HDAC) inhibitors were previously studied as
differentiating agents (Candido et al, 1978; Richon et al, 1998). For
example, HDAC inhibitors synergize with retinoic acid to stimulate
leukaemia cell differentiation (Grignani et al, 1998; Lin et al, 1998;
Kosugi et al, 1999). It has been demonstrated that FR901228 is a
novel histone deacetylase inhibitor (Nakajima et al, 1998). Like
other inhibitors (Sowa et al, 1997), FR901228 induces p21 in a
p53-independent manner (Rajgolikar et al, 1998). However, the
significance of this induction in the mechanism of growth arrest or
cytotoxicity by FR901228 is unclear.
To further characterize the mechanism of action of FR901228,
given its ability to cause G1 and G2/M cell cycle arrest, we inves-
tigated the effect of FR901228 on the regulatory mechanisms
involved in the G1-to-S transition. We report that FR901228
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doi: 10.1054/ bjoc.2000.1327, available online at http://www.idealibrary.com on downregulated cyclin D1 and upregulated CDK inhibitor
p21WAF1/CIP1 resulting in inhibition of CDK activity and Rb dephos-
phorylation and G1 arrest. Cells lacking p21 did not undergo G1
arrest, continued DNA synthesis and were arrested in the G2/M
phase of the cell cycle.
METHODS
Cell lines
MCF-10A is an EGF-dependent immortalized but non-trans-
formed breast cell line derived from human fibrocystic mammary
tissue (Soule et al, 1990). MCF-10A cells were maintained in
DMEM/F12 medium (Biofluids, Rockville, MD, USA) with 5%
horse serum (Gibco BRL, Rockville, MD, USA), 10 ng/ml human
EGF (Upstate Biotechnology, Lake Placid, NY, USA), 500 ng/ml
hydrocortisone (Sigma, St Louis, MO, USA), and 100 ng/ml
bovine insulin (Sigma, St Louis, MO, USA). All other cell lines,
PC-3 (prostate carcinoma), SW620 (colon carcinoma), IGROV
(ovarian carcinoma), DU145 (prostate carcinoma), MCF-7 (breast
carcinoma), and A549 (lung carcinoma) were obtained from the
NCI drug screen and maintained as described previously
(Wosikowski et al, 1996). For p21 studies, the human colon carci-
noma cell line HCT116 and two clones lacking p21 were used. The
clones, S4 and S14 (both p21–/–), were a gift from Dr B
Vogelstein (Johns Hopkins University) and described previously
(Waldman et al, 1996; Blagosklonny et al, 1997; Bunz et al, 1998).
Ad-p21, a p21 expressing adenovirus, was obtained from Dr WS
El-Deiry (University of Pennsylvania, Philadelphia) and the viral
titre was determined as previously described (Blagosklonny et al,
1997). Multiplicity of infection (MOI) is defined as the ratio of
total number of viruses used in a particular infection per number of
cancer cells to be infected (i.e., number of viruses per cell).
Cell cycle analysis
Cells were harvested by trypsinization while in the exponential
growth phase (50–70% confluence). Cells were washed twice with
PBS and resuspended in 75% ethanol in PBS and kept at 4° C for at
least 30 minutes. Prior to analysis, cells were washed again with
PBS and resuspended and incubated for 30 min in propidium iodide
staining solution containing 0.05 mg/ml propidium iodide (Sigma,
St Louis, MO, USA), 1 mM EDTA, 0.1% Triton-X-100 and 
1 mg/ml RNAse A in PBS. The suspension was then passed through
a nylon mesh filter and analysed on a Becton Dickinson FACScan.
Immunoblotting
Cells in 10 cm dishes were scraped into cell lysis buffer containing
20 mM Tris, 150 mM NaCl, 2 mM EDTA, 0.5% NP-40, 0.5%
deoxycholate, and 0.1% SDS, with phosphatase inhibitors (1 mM
sodium orthovanadate and 25 mM NaF) and protease inhibitors
(PMSF, leupeptin and aprotonin). Lysates were clarified by spin-
ning at 14 000 rpm for 15 minutes and protein concentrations
determined using the BioRad colorimetric assay. Proteins were
then separated by standard SDS-PAGE chromatography and
transferred to PVDF (Millipore) membranes by electroblotting in
10 mM CAPS (Sigma, St Louis, MO, USA) buffer at pH 11.0.
Immunoblotting was performed using primary antibodies at the
following dilutions in 1% milk or 4% BSA (for anti-tyrosine phos-
phate anti-activated EGFR) in Tris buffered saline (150 mM NaCl,
20 mM Tris-HCl pH = 7.5) with 0.05% Tween 20: anti-ERK2,
anti-RB, anti-p53, anti p21WAF1, anti-cyclin D1, anti-cyclin E
(Santa Cruz Biotech, Santa Cruz, CA, USA) at 1:100, anti-tyrosine
phosphate, (Signal Transduction Laboratories, Lexington, KY,
USA) at 1:1000, anti-cyclin E (Pharmigen, San Diego, CA, USA)
at 1:1000. Immunoblots were developed using an HRP-conjugated
secondary antibody (Bio Rad) and a chemiluminescence detection
kit (Dupont NEN, Wilminghton, DE, USA).
Immune complex kinase assays
Cells were lysed with buffer containing 50 mM Hepes (pH 7.5),
20 mM EDTA, 0.5% NP 40, 1 mM ABESF, 5 mg/ml aprotinin, 
5 mg/ml leupeptin, 10 mM β -glycerophosphate, 0.5 mM NaF and
0.4 mM NaVO4. The lysate was centrifuged at 15 000 g for 30
min at 4° C. The supernatant was used for protein quantification
and immunoblotting/kinase assays as described below. Four
hundred mg of protein were incubated with 2 ml of CDK4, CDK2,
CDK1 (Gibco BRL, Rockville, MD, USA) and CDK6 antisera
(manuscript in preparation) for 1 h in a shaker at 4° C followed by
the addition of 20 ml Gammabind G Sepharose (Pharmacia,
Piscataway, NJ) suspension (50%). After a further incubation for 
1 h at 4° C, the immunocomplex was centrifugated at 800 g for 
1 min, washed 3 times with lysing buffer containing 0.5 M NaCl,
and once with kinase buffer (50 mM Hepes, pH 7.5, 10 mM
MgCl2, 5 mM MnCl, 1 mM DTT, 10 mM β -glycerophosphate, 2.5
mM EGTA, 0.5 mM NaF, 0.4 mM NaVO4). The kinase reaction
was started by the addition of 30 ml kinase buffer containing 
5 mM ATP 1 mCi of 32P-ATP and 1 mg of GST-Rb (histone H1
for CDK2 and CDK1 from Boehringher Mannheim). The reaction
mixture was incubated for 30 min at 30° C with constant mixing,
and stopped by adding 6 ml of 6  SDS-sample buffer followed by
heating for 5 min at 95° C. After a quick centrifugation, proteins
(30 ml) were separated by SDS-PAGE, using a 12% acrylamide
gel. The gels were dried and radio-labelled substrate was
quantified in a Storm phosphorimager (Molecular Dynamics,
Sunnyvalley, CA, USA).
Cell number
Briefly, 10 000–15 000 cells were plated in 24-well plates in 1 ml
of medium. The next day, cells were treated with depsipeptide.
After 4 days, cells were trypsinized and each condition was counted
in triplicate on a Coulter Z1 cell counter (Hialeah, FL, USA).
DNA synthesis
DNA synthesis was monitored by 3H-thymidine incorporation. In
brief, 2000 cells were plated in 96-well flat bottom plates or 15 000
cells were plated in 24-well plates. The next day, cells were treated
with drugs and incubated for 16 hours. Then, cells were incubated
with 1 µ Ci [methyl3H]-thymidine (Amersham) for an additional 
4 hours and then acid-insoluble radioactivity was determined.
RESULTS
p53-independent cell cycle arrest in a panel of cell lines
To confirm that depsipeptide, FR901228, causes G1 cell cycle
arrest in human cancer cells as previously reported for H-Ras
transformed NIH 3T3 cells (Ueda et al, 1994c), we analysed the
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lines from the NCI anticancer drug screen. Figure 1 shows repre-
sentative cell cycle histograms at three different concentrations of
FR901228. In addition to a G1 cell cycle arrest, a G2 cell cycle
arrest can be seen. The ability of FR901228 to cause a G1 cell
cycle arrest in the p53-null PC3 cell line suggests a p53-indepen-
dent effect. Although the number of PC3 cells in G1 was
unchanged after FR exposure, the disappearance of S cells indi-
cates a G1 arrest. An unchanged number of cells in G1, despite the
disappearance of the S phase cells, can be explained if cells neither
enter G1 (due to G2/M arrest) nor exit G1 (G1 arrest). In the
absence of G1 arrest, cells would accumulate exclusively in G2/M
phase (see for example the p21–/– cells in Figure 7).
Although FR901228 increased both G1 and G2 fractions, higher
doses (100 ng/ml) caused a predominance of the G2 phase arrest.
CHO cells were relatively resistant to FR901228 whereas mini-
mally transformed MCF10 cells were the most sensitive. HCT-15
cells were also resistant to FR901228. However, HCT-15 cells are
known to express significant levels of the multidrug transporter
Pgp, and since FR901228 was previously shown to be a substrate
for efflux by Pgp (Lee et al, 1994), 10 ng/ml verapamil was added
in combination with FR901228. Subsequently, a distinct G1 and
G2 arrest pattern emerged (Figure 1 B).
FR901228 arrested cells in G1 before the restriction
point of DNA synthesis
To further define the G1 cell cycle arrest caused by FR901228, the
immortalized EGF-dependent breast cell line MCF-10A was used
(Figure 2). Synchronization of these cells in G0/G1 was achieved
with 24 h growth factor or serum deprivation (Figure 2A,
Starvation). Following release into serum-containing medium
these cells redistributed normally in the cell cycle within 18 hours
of release (Release). However, when these synchronized cells
were released into serum-containing medium with 10 ng/ml
FR901228, they remained in G0/G1 (Release + FR) in contrast to
the G1 and G2/M arrest that occurs in exponentially growing cells
following FR901228 treatment (FR). Aphidicolin was used to
further define the point at which G1 arrest occurs. Aphidicolin
reversibly inhibits DNA polymerase causing a cell cycle arrest at
the G1/S border after the restriction point (Figure 2B). With
synchronization in G1/S achieved using aphidicolin, cells released
p21-dependent G1 arrest by FR901228 819
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Figure 1 Effects of FR90128 on cell cycle and G1 and G2/M cell cycle arrest. (A) IGROV, PC3, CHO, MCF10 cells were treated with 1 ng/ml, 10 ng/ml, or 
100 ng/ml of FR901228 (FR) or left untreated (control) for 24 h, and cell cycle analysis was performed as described in Methods. The experiments were repeated
three times. (B) HCT-15 cells were treated with 10 ng/ml FR901228 (FR), 10 ng/ml verapamil (VP), or their combination (FR+VP) for 24 h and cell cycle analysis
was performed as described in Methodsinto serum-containing, aphidicolin-free medium redistributed like
exponentially growing cells within the cell cycle at 18 hours
(Figure 2, Release). Cells released from aphidicolin-containing
medium into aphidicolin-free medium containing 10 ng/ml
FR901228, cycled through S phase and were arrested in G2/M
(Release + FR). This suggests that FR901228 causes cell cycle
arrest in early G1, before the G1/S restriction point, and also
confirms the G2/M arrest.
FR901228 induced Rb dephosphorylation
The retinoblastoma protein (Rb) is a central regulatory protein in
the G1-to-S transition (Weinberg, 1995). Inactivation of Rb
through hyperphosphorylation by cyclin dependent kinase (CDK)
complexes such as cyclin D/CDK4 and cyclin E/CDK2 causes the
release of the E2F transcription factor which in turn controls the
transcription of genes required for the G1-to-S transition
(DeGregori et al, 1995; Nevins, 1998; Sherr, 1999). Conversely,
hypophosphorylated forms of Rb bind to the E2F family of
transcription factors preventing their action and, complexed to
E2F, act as active transcriptional repressors preventing cell cycle
progression (Zhang et al, 1999). The immunoblot for Rb in Figure
3 shows a time course for MCF-10A and PC-3 cells treated with
FR901228. Several bands can be seen representing Rb protein,
with the higher molecular weight bands representing hyper-
phosphorylated forms of Rb and the lower molecular weight bands
representing hypophosphorylated forms of Rb. Within 6–8 hours
of treatment with 10 ng/ml of FR901228, the hypophosphorylated
forms of Rb predominate in both MCF-10A cells and PC-3 cells.
After 12 hours of treatment, Rb is almost completely in the
hypophosphorylated form in both cell lines. In addition to 
pRb dephosphorylation, the overall level of pRb appears to be
upregulated. As suggested by Juan et al, the increase in quantity of
Rb may act as an additional factor arresting cells in G1, as
observed during cell differentiation (Juan et al, 1998).
FR901228 inhibits CDK by an indirect mechanism
Next, in vitro kinase assays were performed to examine the effect
of FR901228 on CDK2 and CDK4 activity. CDK2 and CDK4
were immunoprecipitated from exponentially growing PC3 cells
and kinase assays performed in the presence or absence of 1, 10,
and 100 ng/ml of FR901228. No direct CDK2 or CDK4 inhibition
by FR901228 was noted (data not shown). Figure 4 shows the
results of a similar experiment performed in living cells. PC3 cells
were treated with FR901228, and CDK were then precipitated
from extracts of these cells, and in vitro kinase assays performed.
Inhibition of CDK2, 4 and 6 activity was noted after treatment of
cells with FR901228 (Figure 4). The in vivo inhibition in the
absence of in vitro inhibition suggests that depsipeptide is acting
on pathways upstream of CDK.
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A Starvation Release Release + FR FR
B Aphidicolin Release Release + FR
Figure 2 Effects of FR901228 on cell cycle distribution in MCF10 cells
synchronized by serum starvation (A) or aphidicolin (B). (A) Effects of
FR901228 on G1 progression in G0-synchronized MCF10 cells. MCF10 cells
can be arrested in G0/G1 due to 24 h serum starvation (Starvation).
Following a release into serum-containing medium (Release), cells resume S
phase. Cells released into serum-containing medium with 10 ng/ml FR
(Release + FR) maintain the cell cycle arrest in G1. Unsynchronized MCF10
cells treated with 10 ng/ml FR for 16 h (FR) show a G1 and a G2/M arrest.
The experiments were repeated 3 times. (B) Effects of the Aphidicolin-
pretreatment on the growth arrest caused by FR901228. MCF10 cells were
synchronized by treatment with 3 µ M aphidicolin for 24 h (Aphidicolin). After
synchronization with aphidicolin, cells were released into aphidicolin-free
medium for 18 h (Release), or into aphidicolin-free medium containing 
10 ng/ml FR for 18 h (Release+FR)
pRb
Rb
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Figure 3 Effects of FR901228 on Rb phosphorylation. MCF10A and PC3
cells were treated with 10 ng/ml FR901228 (FR) for the indicated time and
immunoblot for Rb was performed as described in Methods. The experiments
were repeated 3 times
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Figure 4 Effects of FR901228 on CDK activities in vivo. MCF10A cells and
PC3 cells were treated with 1 ng/ml, 10 ng/ml, and 100 ng/ml FR for 14 h and
measurement of CDK kinase activity was performed as described in the
Methods. The representative results of three experiments are shownFR901228 down-regulated cyclin D1 and up-regulated
p21
Because CDKs are activated by cyclins and inhibited by CDK
inhibitors such as p21, we examined the effect of FR901228 on
cyclin D1 and p21. Cyclin D1 was found to be decreased by 6 h
and absent after 12 h of treatment with 10 ng/ml of FR901228 in
MCF-7, MCF-10A and PC3 cells (Figure 5). In contrast, an
increase in cyclin E was observed after treatment with FR901228.
An increase in cyclin E should result in rescue of the CDK activity
unless an inhibitor of the complex is present.
p21WAF1/CIP1 is capable of inhibiting both G1- and G2-
cyclin/CDK complexes, thus causing both a G1 and G2 cell cycle
arrest. In addition to wt p53 (El-Deiry et al, 1993), numerous
compounds induce p21 independently of p53. Induction of p21
with down-regulation of wt p53 is noted in MCF-10A (Figure 6).
Also, p21 was induced by 12 h in PC3 cells associated with both
G1 and G2/M arrest (Figure 6B). Thus, FR901228 causes p21
WAF1 induction independently of p53. This result is compatible
with the p53 independence of FR901228 action noted in Figure 1.
p21 was required for G1 arrest but not for cytotoxicity
Since p21 was induced by FR901228, we next investigated the
significance of that induction in FR901228-mediated growth
arrest. We took advantage of the availability of two clones of the
HCT116 colon cancer cell line, designated as S4 and S14, which
were engineered to lack the p21 gene. These two p21-knockout
clones differ from parental HCT116 cells only by the missing p21
genes (Waldman et al, 1995, 1996; Bunz et al, 1998). As expected,
p21 protein was undetected in p21–/– clones (Figure 7 A and data
not shown) but was induced by FR901228 in HCT116 cells
(Figure 7 A). Cyclin D1 was downregulated in both parental
HCT116 and p21–/– cells following FR901228 treatment (Figure
7 A). Absence of p21 in cells corresponded to failure of FR901228
to cause G1 arrest and to inhibit 3H-thymidine incorporation
indicating ongoing DNA synthesis in cells lacking the p21 genes
(Figure 7 B, C). The cell cycle distribution was similar in untreated
clones and parental cells (Figure 7 B). However, following 
24 hours of exposure to 10 ng/ml FR901228, HCT116 cells were
arrested in both G1 and G2/M phases of the cell cycle. In contrast,
p21-deficient S4 and S14 clones were arrested exclusively in
G2/M phase but not in G1 phase. This lack of G1 arrest confirmed
the ability of p21-deficient clones to continue DNA synthesis (3H-
thymidine incorporation) following FR901228 treatment (Figure 
7 C).
Further, FR901228 was not only toxic to p21-deficient cells but
was more toxic than to parental cells. Thus, following 2 days of
treatment with 10 ng/ml of FR901228 approximately 16% of
parental HCT116 cells survived whereas only 3–4% of S4 cells
could be detected (Figure 7D). Comparable cytotoxicity in
HCT116 cells required an additional 24–48 h of exposure.
Cytoprotective role of p21 induction and G1 arrest was previously
demonstrated in p53-mediated apoptosis in HCT116 cells (Polyak
et al, 1996). Our result suggests that the G2/M arrest may be more
effective in achieving cell death than the G1 arrest following
FR901228 treatment.
We next examined the effects of p21 on cell cycle distribution in
HCT116 following infection of these cells with p21-expressing
adenovirus. Following p21 overexpression, the number of cells in
G1 phase was increased from 52% to 75%, the number of cells in
p21-dependent G1 arrest by FR901228 821
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Figure 5 Effects of FR901228 on cyclin D and cyclin E. MCF-7, MCF10A,
and PC3 cells were treated with 10 ng/ml FR for the indicated times and
immunoblot for cyclin D1 and cyclin E were performed as described in
Methods
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Figure 6 Effects of FR901228 on the p53-independent induction of p21 and
growth arrest. (A) MCF10A (wt p53) cells were treated with 10 ng/ml FR for
the indicated times or with 100 ng/ml paclitaxel (PTX) and immunoblot
analysis for p53 and p21 was performed as described in the Methods.
(B) PC3 (p53-null) cells were treated with 10 ng/ml FR for 12 h and
immunoblot for p21 was performed as described in the Methods. Cell cycle
distribution of PC3 cells by 16 h of treatment is shown belowS phase was decreased from 30% to 10% and the number of G2/M
cells was unchanged (18% and 16%, respectively). Therefore,
overexpression of p21 alone (without FR901228) exerts growth
arrest in the G1 phase in HCT116 cells, whereas the absence of
endogenous p21 in p21–/– cells precludes G1 growth arrest.
FR901228 prevented MAPK activation but not tyrosine
phosphorylation
Growth factor (GF) signalling is required for the passage of
normal cells from G0/G1 through the restriction point and into the
cell cycle (Pardee, 1974). These signalling pathways represent an
upstream regulatory component of CDK activity and Rb phos-
phorylation state. GF activates several signal transduction pathways
including the ERK2/MAPK pathway. MCF-10A cells were used to
examine the effect of FR901228 on signal transduction through
MAPK. Figure 8A shows a mobility shift assay for activation of
ERK-2 in MCF-10A cells that were serum starved for 24 hours,
exposed to 0, 1, 10, or 100 ng/ml of FR901228 for 16 hours; and
then stimulated with 10 ng/ml EGF for 5 minutes before
harvesting. The first lane shows the control, which received no
EGF stimulation or treatment with FR901228, and as expected
shows no shift in the mobility of the ERK-2 band. The next lane
demonstrates the MAPK phosphorylation after EGF stimulation,
in the absence of FR901228. The subsequent three lanes show a
dose-dependent decrease in the overall quantity of ERK-2 activa-
tion relative to the quantity that remains inactive.
Early events in the EGF signal transduction pathway involve
sequential tyrosine phosphorylation of proteins (Hunter, 1997).
The effect of FR901228 on early tyrosine phosphorylation 
events was examined to determine whether FR901228 disrupts 
the EGF/MAPK pathway through direct inhibition of tyrosine
822 V Sandor et al
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Figure 7 The role of p21 in the G1 arrest and cytotoxicity caused by FR901228. (A) Immunoblot analysis of cyclin D1 and p21 following FR treatment. S4, a
p21-deficient clone, and parental HCT116 cells were treated with 10 ng/ml FR for the indicated times and immunoblots for cyclin D1 and p21 were performed as
described in the Methods. (B) Cell cycle distribution. Parental HCT116 cells and S4 and S14 clones lacking p21 were treated with 10 ng/ml FR901228 (FR) or
left untreated (control) for 24 h, and cell cycle analysis was performed as described in the Methods. (C) Parental HCT116 cells (closed circles) and S4 cells
lacking p21 (open squares) were treated with indicated concentrations of FR (ng/ml) for 16 h, and 3H-thymidine incorporation was performed in triplicate as
described in the Methods. Results represent percent of the control value in untreated cells (mean ± SD). (D) Parental HCT116 cells (open bars) and S4 cells
lacking p21 (closed bars) were treated with 10 ng/ml FR for the indicated time, and the number of live cells was counted in triplicate as described in the
Methods. Results represent percent of value of untreated cells (mean ± SD).phosphorylation. An immunoblot of cell lysates prepared as
described above was probed for phosphotyrosine using an
antiphosphotyrosine antibody (Figure 8 B). The first lane shows a
low level of tyrosine phosphorylation in lysates from serum
deprived cells. Lysates from cells stimulated with EGF for 5
minutes after treatment with 0, 1, 10 and 100 ng/ml of FR901228
show no differences in overall tyrosine phosphorylation
suggesting that depsipeptide does not act as a general tyrosine
kinase inhibitor, and also that FR901228 does not disrupt early
signal transduction events regulated by tyrosine phosphorylation.
DISCUSSION
We have characterized an aspect of the mechanism of action of
FR901228 by defining its effect on pathways that regulate G1-to-S
transition. Cell cycle studies using synchronized populations of
MCF-10A cells suggest that FR901228 blocks cell cycle progres-
sion before the G1 phase restriction point. Consistently, Rb protein
becomes hypophosphorylated after 6 hours of treatment with
FR901228. This hypophosphorylation can be explained by a
decrease in CDK activity seen after cells are exposed to
FR901228. This drop in kinase activity seems to result from a
decrease in cyclin D1 protein, a CDK activator, and an increase in
p21 protein, a CDK inhibitor, after exposure to the drug. These
changes were accompanied by a decrease in cyclin D1 mRNA and
increase in p21 mRNA (data not shown). This identified
FR901228 as a compound capable of inducing p21 independently
of p53. Furthermore, cells without p21 expression did not undergo
FR901228-mediated G1 arrest. This provides evidence for p21
induction as the mediator for the G1 arrest caused by FR901228.
The D family of cyclins act as growth factor sensors and are
induced as a response to growth factor stimulation (Sherr, 1999).
Our findings show that FR901228 disrupts signal transduction
through the ERK2/MAPK pathway. Overall cellular tyrosine
phosphorylation in response to EGF stimulation remains intact
suggesting that immediate events at the EGF pathway are not
disrupted. We conclude that the G1 cell cycle arrest caused by
FR901228 can be explained by disruption of signal transduction
leading to down-regulation of cyclin D1. The only known
biochemical activity of FR901228 is inhibition of histone de-
acetylase (Nakajima et al, 1998). Our findings are consistent with
results that have been observed with other agents known to inhibit
histone deacetylases. Oxamflatin, another histone deacetylase
inhibitor, increased transcriptional expression of cyclin E and
CDK inhibitor p21 and decreased expression of cyclin D1 (Kim et
al, 1999). Butyrate is another histone deacetylase inhibitor which
in millimolar concentrations causes G1 arrest before the restriction
point of G1/S progression (Campisi et al, 1982; Vaziri et al, 1998).
Importantly, FR901228 caused G1 arrest and cytotoxicity at
nanomolar concentrations, thus showing at least 100 000-fold
higher activity than butyrate.
In normal cells, induction of p21, a CDK inhibitor, opposes the
effects of cyclins D and E on CDK which enables it to interrupt the
cell cycle (Sherr, 1999). However, cyclin levels are not normally
reduced by p21 induction (Chen et al, 1995). While it has been
reported that growth arrest by butyrate was mediated by p21 in
HCT116 cells (Archer et al, 1998), another group found that p21
induction is dispensable for the G1 arrest by butyrate in mouse
fibroblasts (Vaziri et al, 1998). In contrast to studies in fibroblasts
(Vaziri et al, 1998) and MOLT-4 cells (Gong et al, 1994) that
demonstrated a decrease in cyclin E following butyrate treatment,
in our study, FR901228 up-regulated cyclin E in human cancer cell
lines. While our manuscript was under review, it was reported that
Rb forms a repressor containing histone deacetylase which inhibits
transcription of genes for cyclins E (Zhang et al, 2000). 
If cells are arrested by serum starvation in G0, cyclin D levels
are diminished, and Rb, the substrate of the cyclin D-activated
CDK, is hypophosphorylated. FR901228 can maintain this status
and prevent induction of cyclin D1 and Rb phosphorylation,
causing G1 arrest. It has been shown that, while E2F induces
cyclin E (Botz et al, 1996), dephosphorylated Rb complexed with
E2F actively blocks cyclin E expression, thus preventing the next
step of cell cycle progression (Zhang et al, 1999).
Thus, the apparent contradictory down-regulation of cyclin D1
and up-regulation of cyclin E may be explained by the inhibitory
effects of FR901228 on histone deacetylase. Dephosphorylated Rb
complexes with E2F, and recruiting a histone deacetylase, exerts
active transcriptional repression (Brehm et al, 1998; Luo et al, 1998;
Magnaghi-Jaulin et al, 1998; Zhang et al, 1999). Therefore, histone
deacetylase may be responsible for repression of cyclin E during
natural G1 arrest. FR901228, by inhibiting histone deacetylase may
prevent cyclin E down-regulation. Simultaneously, inhibition of
p21-dependent G1 arrest by FR901228 823
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Figure 8 Effects of FR901228 on the MAPK pathway and tyrosine kinase
activation. MCF 10 cells were synchronized in serum-free medium (SF), and
then stimulated with 10 ng/ml EGF for five minutes. As shown, cells were
pretreated with the indicated doses of FR for 16 hours prior to lysis. Cells
were lysed and an immunoblot for ERK2 (A) and total phosphotyrosine (B)
was performed as described in the Methods.histone deacetylase transcriptionally induces p21 (Sowa et al,
1997), which we observed following FR901228 treatment. It is
noteworthy that while cyclins D1 and E, and the CDK inhibitor
p21 are commonly induced in parallel (Blagosklonny, 1999),
FR901228 treatment resulted in a unique combination: increased
p21 and cyclin E accompany decreased cyclin D1.
This induction of cyclin E, despite cyclin D down-regulation
and initial Rb dephosphorylation, could move cells into S phase.
However, p21 is also induced at the time of cyclin E induction, and
it has been shown that p21 can inhibit cyclin E-driven initiation of
S phase (Stewart et al, 1999). Therefore, increased p21 counter-
balances increased cyclin E following FR901228 treatment.
Sustained G1 arrest, which is initially triggered by downregulation
of cyclin D1, thus depends on p21 expression. Cells lacking p21
(p21–/– cells) enter S phase and arrest in G2/M. p21 induction was
dispensable for G1 arrest by butyrate in MEF cells in which
butyrate down-regulated cyclin E (Vaziri et al, 1998). If both
cyclins D and E are down-regulated, induction of p21 becomes
dispensable for growth arrest. Thus, the difference in cyclin E
regulation may determine the requirement for p21 induction by
FR901228. In contrast, neither the G2/M arrest nor cytotoxicity of
depsipeptide depends on p21. Therefore, this promising experi-
mental therapeutic may have several targets that determine its
unique cytotoxic profile. Further studies will define the associa-
tion between the G1 cell cycle arrest caused by FR901228 and its
ability to induce G2/M-associated cytotoxic effects.
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